325 related articles for article (PubMed ID: 11278610)
21. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Lacronique V; Boureux A; Valle VD; Poirel H; Quang CT; Mauchauffé M; Berthou C; Lessard M; Berger R; Ghysdael J; Bernard OA
Science; 1997 Nov; 278(5341):1309-12. PubMed ID: 9360930
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation.
Haan S; Ferguson P; Sommer U; Hiremath M; McVicar DW; Heinrich PC; Johnston JA; Cacalano NA
J Biol Chem; 2003 Aug; 278(34):31972-9. PubMed ID: 12783885
[TBL] [Abstract][Full Text] [Related]
23. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor.
Ali S; Nouhi Z; Chughtai N; Ali S
J Biol Chem; 2003 Dec; 278(52):52021-31. PubMed ID: 14522994
[TBL] [Abstract][Full Text] [Related]
24. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling.
Pezet A; Favre H; Kelly PA; Edery M
J Biol Chem; 1999 Aug; 274(35):24497-502. PubMed ID: 10455112
[TBL] [Abstract][Full Text] [Related]
25. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist.
Waiboci LW; Ahmed CM; Mujtaba MG; Flowers LO; Martin JP; Haider MI; Johnson HM
J Immunol; 2007 Apr; 178(8):5058-68. PubMed ID: 17404288
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Bousquet C; Susini C; Melmed S
J Clin Invest; 1999 Nov; 104(9):1277-85. PubMed ID: 10545526
[TBL] [Abstract][Full Text] [Related]
27. Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling.
van de Geijn GJ; Gits J; Touw IP
J Leukoc Biol; 2004 Jul; 76(1):237-44. PubMed ID: 15107455
[TBL] [Abstract][Full Text] [Related]
28. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.
Ungureanu D; Saharinen P; Junttila I; Hilton DJ; Silvennoinen O
Mol Cell Biol; 2002 May; 22(10):3316-26. PubMed ID: 11971965
[TBL] [Abstract][Full Text] [Related]
29. Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II.
Chung AS; Guan YJ; Yuan ZL; Albina JE; Chin YE
Mol Cell Biol; 2005 Jun; 25(11):4716-26. PubMed ID: 15899873
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function.
Flowers LO; Johnson HM; Mujtaba MG; Ellis MR; Haider SM; Subramaniam PS
J Immunol; 2004 Jun; 172(12):7510-8. PubMed ID: 15187130
[TBL] [Abstract][Full Text] [Related]
31. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase.
Babon JJ; Sabo JK; Soetopo A; Yao S; Bailey MF; Zhang JG; Nicola NA; Norton RS
J Mol Biol; 2008 Sep; 381(4):928-40. PubMed ID: 18590740
[TBL] [Abstract][Full Text] [Related]
32. Role of SOCS and VHL Proteins in Neuronal Differentiation and Development.
Kanno H; Matsumoto S; Yoshizumi T; Nakahara K; Kubo A; Murata H; Shuin T; U HS
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835292
[TBL] [Abstract][Full Text] [Related]
33. SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.
Tomic S; Chughtai N; Ali S
Mol Cell Endocrinol; 1999 Dec; 158(1-2):45-54. PubMed ID: 10630404
[TBL] [Abstract][Full Text] [Related]
34. Modulation of Janus kinase 2 by cisplatin in cancer cells.
Song H; Sondak VK; Barber DL; Reid TJ; Lin J
Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
[TBL] [Abstract][Full Text] [Related]
35. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein.
Pause A; Peterson B; Schaffar G; Stearman R; Klausner RD
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9533-8. PubMed ID: 10449727
[TBL] [Abstract][Full Text] [Related]
36. BC-box protein domain-related mechanism for VHL protein degradation.
Pozzebon ME; Varadaraj A; Mattoscio D; Jaffray EG; Miccolo C; Galimberti V; Tommasino M; Hay RT; Chiocca S
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18168-73. PubMed ID: 24145437
[TBL] [Abstract][Full Text] [Related]
37. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.
Sasaki A; Yasukawa H; Suzuki A; Kamizono S; Syoda T; Kinjyo I; Sasaki M; Johnston JA; Yoshimura A
Genes Cells; 1999 Jun; 4(6):339-51. PubMed ID: 10421843
[TBL] [Abstract][Full Text] [Related]
38. Targeting Lyn tyrosine kinase through protein fusions encompassing motifs of Cbp (Csk-binding protein) and the SOCS box of SOCS1.
Whiting RJ; Payne CJ; Satiaputra J; Kucera N; Qiu TW; Irtegun S; Gunn NJ; Slavova-Azmanova NS; Mulhern TD; Ingley E
Biochem J; 2012 Mar; 442(3):611-20. PubMed ID: 22364282
[TBL] [Abstract][Full Text] [Related]
39. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
Melzner I; Bucur AJ; Brüderlein S; Dorsch K; Hasel C; Barth TF; Leithäuser F; Möller P
Blood; 2005 Mar; 105(6):2535-42. PubMed ID: 15572583
[TBL] [Abstract][Full Text] [Related]
40. Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase.
Brower CS; Sato S; Tomomori-Sato C; Kamura T; Pause A; Stearman R; Klausner RD; Malik S; Lane WS; Sorokina I; Roeder RG; Conaway JW; Conaway RC
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10353-8. PubMed ID: 12149480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
